Telix Pharmaceuticals (ASX:TLX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Telix Pharmaceuticals (ASX:TLX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - TLX
Notification regarding unquoted securities - TLX
Application for quotation of securities - TLX
FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
Telix wins FDA Fast Track designation for pre-biopsy prostate cancer imaging program
Change in substantial holding
Appendix 3Y Change in Director Interest-D Gill
Application for quotation of securities - TLX
Grant of waivers of Listing Rule 7.3.4
Telix and ITM Join Forces to Create Radiopharma Powerhouse
Telix proposes US$1.65B acquisition of ITM to build integrated radiopharmaceutical platform
Telix and ITM Join Forces to Create Radiopharma Powerhouse
Telix agrees to acquire ITM in US$1.65 billion radiopharmaceutical merger
Application for quotation of securities - TLX
FDA Approves Telix Brain Cancer Imaging Drug Pixclara
FDA approves Telix's Pixclara as first glioma-specific FET-PET imaging drug in the US
Telix Completes Enrollment in Phase 3 BiPASS Study
Telix Completes Phase 3 BiPASS Enrollment and Aligns with FDA on NDA Pathway for Prostate Cancer Imaging
Telix Appoints David Gill as Chair
Telix HY26 Results Presentation
Telix Pharmaceuticals reports strong H1 2026 growth, advances clinical pipeline, and raises FY revenue guidance
Telix HY26 Results Announcement
Telix Pharmaceuticals H1 2026 Results Show Strong Revenue Growth and Pipeline Progress
Telix HY26 Appendix 4D and Interim Report
Telix Pharmaceuticals reports H1 2026 profit of $38.3M on 22% revenue growth, expands R&D and partners with Regeneron
Telix H1 2026 Results - Investor Webcast Notification
Change in substantial holding
Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
Telix reports Q2 2026 revenue of US$247M, confirms FY guidance above US$1B, advances clinical pipeline and secures Regeneron collaboration
